| pubmed-article:15801825 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15801825 | lifeskim:mentions | umls-concept:C0067685 | lld:lifeskim |
| pubmed-article:15801825 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:15801825 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:15801825 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:15801825 | pubmed:dateCreated | 2005-4-1 | lld:pubmed |
| pubmed-article:15801825 | pubmed:abstractText | Two representative glutamate carboxypeptidase II (GCP II) inhibitors, 2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid 2 and 2-(3-mercaptopropyl)pentanedioic acid 3, were synthesized in high optical purities (>97%ee). The two enantiomers of 2 were prepared from previously reported chiral intermediates, (R)- and (S)-2-(hydroxyphosphinoylmethyl)pentanedioic acid benzyl esters 8. The synthesis of (R)- and (S)-3 involves the hydrolysis of (R)- and (S)-3-(2-oxo-tetrahydro-thiopyran-3-yl)propionic acids, (R)- and (S)-11, the corresponding optically pure thiolactones delivered by chiral chromatographic separation of the racemic 11. GCP II inhibitory assay revealed that (S)-2 is 40-fold more potent than (R)-2. In contrast, both enantiomers of 3 inhibited GCP II with nearly equal potency. The efficacy observed in subsequent animal studies with these enantiomers correlated well with the inhibitory potency in a GCP II assay. | lld:pubmed |
| pubmed-article:15801825 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15801825 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15801825 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15801825 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15801825 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:WuYingY | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:WozniakKrysty... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:SlusherBarbar... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:MajerPavelP | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:TsukamotoTaka... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:HinBundaB | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:VitharanaDilr... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:ThomasAjit... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:LuXi-Chun MXC | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:NiChiyouC | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:CalvinDavid... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:ScarpettiDavi... | lld:pubmed |
| pubmed-article:15801825 | pubmed:author | pubmed-author:BonnevilleGeo... | lld:pubmed |
| pubmed-article:15801825 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15801825 | pubmed:day | 7 | lld:pubmed |
| pubmed-article:15801825 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:15801825 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15801825 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15801825 | pubmed:pagination | 2319-24 | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:meshHeading | pubmed-meshheading:15801825... | lld:pubmed |
| pubmed-article:15801825 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15801825 | pubmed:articleTitle | Enantiospecificity of glutamate carboxypeptidase II inhibition. | lld:pubmed |
| pubmed-article:15801825 | pubmed:affiliation | Guilford Pharmaceuticals Inc., 6611 Tributary Street, Baltimore, Maryland 21224, USA. tsukamoto@guilfordpharm.com | lld:pubmed |
| pubmed-article:15801825 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:15801825 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801825 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15801825 | lld:pubmed |
